IL278188B2 - Sublingual formulation of riluzole - Google Patents

Sublingual formulation of riluzole

Info

Publication number
IL278188B2
IL278188B2 IL278188A IL27818820A IL278188B2 IL 278188 B2 IL278188 B2 IL 278188B2 IL 278188 A IL278188 A IL 278188A IL 27818820 A IL27818820 A IL 27818820A IL 278188 B2 IL278188 B2 IL 278188B2
Authority
IL
Israel
Prior art keywords
dosage form
pharmaceutical dosage
riluzole
pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
IL278188A
Other languages
English (en)
Hebrew (he)
Other versions
IL278188B1 (en
IL278188A (en
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of IL278188A publication Critical patent/IL278188A/en
Publication of IL278188B1 publication Critical patent/IL278188B1/en
Publication of IL278188B2 publication Critical patent/IL278188B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL278188A 2014-11-21 2015-11-17 Sublingual formulation of riluzole IL278188B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083094P 2014-11-21 2014-11-21
PCT/US2015/061114 WO2016081472A1 (en) 2014-11-21 2015-11-17 Sublingual formulation of riluzole

Publications (3)

Publication Number Publication Date
IL278188A IL278188A (en) 2020-11-30
IL278188B1 IL278188B1 (en) 2024-11-01
IL278188B2 true IL278188B2 (en) 2025-03-01

Family

ID=55085882

Family Applications (2)

Application Number Title Priority Date Filing Date
IL278188A IL278188B2 (en) 2014-11-21 2015-11-17 Sublingual formulation of riluzole
IL252285A IL252285B (en) 2014-11-21 2017-05-15 Sublingual formulation of riluzole

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL252285A IL252285B (en) 2014-11-21 2017-05-15 Sublingual formulation of riluzole

Country Status (24)

Country Link
US (3) US11660267B2 (enExample)
EP (3) EP3616686B8 (enExample)
JP (3) JP6753860B2 (enExample)
KR (2) KR102580378B1 (enExample)
CN (1) CN107249567B (enExample)
AU (2) AU2015350148B2 (enExample)
BR (1) BR112017010423B1 (enExample)
CA (1) CA2967662A1 (enExample)
CY (1) CY1122469T1 (enExample)
DK (1) DK3220891T3 (enExample)
EA (1) EA038518B1 (enExample)
ES (2) ES2751300T3 (enExample)
HR (1) HRP20191892T8 (enExample)
HU (1) HUE046869T2 (enExample)
IL (2) IL278188B2 (enExample)
LT (1) LT3220891T (enExample)
MX (1) MX368838B (enExample)
PH (1) PH12017500934B1 (enExample)
PL (1) PL3220891T3 (enExample)
PT (1) PT3220891T (enExample)
RS (1) RS59490B1 (enExample)
SG (1) SG11201703896QA (enExample)
SI (1) SI3220891T1 (enExample)
WO (1) WO2016081472A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017341723B2 (en) 2016-10-11 2021-12-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP7354123B2 (ja) * 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法
KR20210024475A (ko) * 2018-05-27 2021-03-05 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
EA202190544A1 (ru) * 2018-08-16 2021-06-18 Биохэйвен Терапьютикс Лтд. Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
CA3158411A1 (en) * 2019-10-22 2021-04-29 Arvinas Operations, Inc. Methods of treating prostate cancer
PE20231204A1 (es) 2020-05-09 2023-08-17 Arvinas Operations Inc Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo
US20240016783A1 (en) * 2020-10-05 2024-01-18 Icahn School Of Medicine At Mount Sinai Riluzole for the treatment of alzheimer's disease
US20240000808A1 (en) 2020-11-16 2024-01-04 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113876735B (zh) * 2021-10-20 2023-05-12 陇南市第一人民医院 一种利鲁唑微球制剂及其制备方法
KR102625977B1 (ko) 2021-11-24 2024-01-17 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864008A1 (en) * 2012-03-01 2013-09-06 Pharnext New compositions for treating amyotrophic lateral sclerosis

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
JP3233638B2 (ja) 1993-07-09 2001-11-26 アール．ピー． シェーラー コーポレイション 凍結乾燥された薬投与形状物の製造方法
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
HUP0000393A3 (en) * 1996-12-20 2000-12-28 Nutrinova Gmbh Method for increasing the sweetening power and enhancing the taste of a mixture of extremely powerful sweetening agents
US6471992B1 (en) 1997-02-20 2002-10-29 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
EP1001748B1 (en) 1997-07-25 2006-04-19 Alpex Pharma S.A. A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
HUP0105089A3 (en) 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
ATE289800T1 (de) 1998-12-09 2005-03-15 Chiron Corp Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6432992B1 (en) * 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7993674B2 (en) 2002-02-13 2011-08-09 Weibel Michael K Drug dose-form and method of manufacture
WO2004105756A2 (en) * 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
JP5269894B2 (ja) 2007-06-27 2013-08-21 ハンミ ファーム． シーオー．， エルティーディー． 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
US20110183942A1 (en) * 2008-07-15 2011-07-28 University Of Medicine And Dentistry Of New Jersey Methods and Compositions for Treating Alzheimer's Disease
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
WO2010096869A1 (en) * 2009-02-26 2010-09-02 Steven Michael Weiss An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
SI2727588T1 (sl) * 2011-03-01 2019-03-29 Pharnext Na baklofenu in akamprosatu temelječa terapija nevroloških motenj
EA028060B1 (ru) * 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
EP3220890A1 (en) 2014-11-21 2017-09-27 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
HRP20220208T1 (hr) * 2015-03-03 2022-04-29 Biohaven Therapeutics Ltd. Prolijekovi riluzola i njihova primjena

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864008A1 (en) * 2012-03-01 2013-09-06 Pharnext New compositions for treating amyotrophic lateral sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PITTENGER C ET AL.,, RILUZOLE IN THE TREATMENT OF MOOD AND ANXIETY DISORDERS, 29 August 2012 (2012-08-29) *

Also Published As

Publication number Publication date
US11660267B2 (en) 2023-05-30
MX2017006446A (es) 2018-02-12
ES2882783T3 (es) 2021-12-02
CY1122469T1 (el) 2021-01-27
DK3220891T3 (da) 2019-11-04
EP4039247C0 (en) 2025-11-05
SG11201703896QA (en) 2017-06-29
PL3220891T3 (pl) 2020-08-24
HRP20191892T1 (hr) 2020-01-10
PT3220891T (pt) 2019-10-31
EP4039247A3 (en) 2022-11-16
EP3616686B1 (en) 2021-05-19
KR20170137032A (ko) 2017-12-12
AU2021201034A1 (en) 2021-03-11
US20210038499A1 (en) 2021-02-11
US12121609B2 (en) 2024-10-22
US20180153794A1 (en) 2018-06-07
EP3616686A1 (en) 2020-03-04
PH12017500934B1 (en) 2024-06-28
AU2015350148A1 (en) 2017-06-15
HUE046869T2 (hu) 2020-04-28
US20250114301A1 (en) 2025-04-10
HRP20191892T8 (hr) 2020-09-18
PH12017500934A1 (en) 2017-11-20
CN107249567B (zh) 2021-08-03
KR102580378B1 (ko) 2023-09-19
WO2016081472A1 (en) 2016-05-26
CA2967662A1 (en) 2016-05-26
IL278188B1 (en) 2024-11-01
EP4039247A2 (en) 2022-08-10
EP3220891B1 (en) 2019-07-24
EA038518B1 (ru) 2021-09-09
BR112017010423A2 (pt) 2017-12-26
LT3220891T (lt) 2019-11-11
EP3220891A1 (en) 2017-09-27
JP2017535613A (ja) 2017-11-30
JP2021001173A (ja) 2021-01-07
CN107249567A (zh) 2017-10-13
SI3220891T1 (sl) 2020-02-28
KR20230135183A (ko) 2023-09-22
AU2015350148B2 (en) 2020-11-26
JP2023065398A (ja) 2023-05-12
BR112017010423B1 (pt) 2023-09-26
MX368838B (es) 2019-10-18
EP4039247B1 (en) 2025-11-05
KR102811263B1 (ko) 2025-05-23
IL278188A (en) 2020-11-30
EP3616686B8 (en) 2021-06-23
EA201790958A1 (ru) 2018-01-31
IL252285B (en) 2020-10-29
AU2021201034B2 (en) 2023-07-06
JP6753860B2 (ja) 2020-09-09
RS59490B1 (sr) 2019-12-31
ES2751300T3 (es) 2020-03-31
IL252285A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
IL278188B2 (en) Sublingual formulation of riluzole
IL305908B2 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2010522137A5 (enExample)
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
JP2012502047A5 (enExample)
NZ784949A (en) Ripretinib for treating gastrointestinal stromal tumors
UA116334C2 (uk) Тверді форми дозування бендамустину
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
JP2011168580A (ja) 医薬組成物
JP2015520221A5 (enExample)
RU2009116816A (ru) Педиатрические таблетки, содержащие капецитабин
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
IL254641B2 (en) Methods and preparations including naproxen and fexofenamide for relieving symptoms of dizziness associated with alcohol consumption
TN2009000390A1 (en) Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma
Sturn et al. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2013216632A (ja) 医薬組成物
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
JP2016056166A (ja) 経口用医薬組成物
JP6940265B2 (ja) 止瀉剤組成物
JP6830482B2 (ja) 粘膜病変の治療のための配合物
JP7119650B2 (ja) 鎮痛剤